{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:06:02Z","timestamp":1761930362274,"version":"3.41.2"},"reference-count":11,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>It has been described in mice models that myeloproliferative neoplasm (MPN) with JAK2\u2010V617F mutation has an increased expression of programmed death\u2010ligand 1 (PD\u2010L1) in megakaryocytes leading to cancer immune evasion by inhibiting the T\u2010lymphocytes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To quantify and compare the PD\u2010L1 expression on bone marrow (BM) of patients with MPN JAK2 positive, negative, and normal controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected BM of patients with MPN JAK2 positive, negative and normal controls from 1990 to 2019. We also created a scoring system to quantify PD\u2010L1 expression in megakaryocytes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We obtained 14 BM with JAK2 positive PMF, 5 JAK2 negative PMF, and 10 patients with normal BM biopsies. PD\u2010L1 expression was higher in the JAK2 positive group compared with the control group with a score of 212.6 versus 121.1 (<jats:italic>t<\/jats:italic>\u2010value 2.05, <jats:italic>p<\/jats:italic>\u2010value 0.025). In addition, the score was higher in the PMF group regardless of JAK2 mutational status when compared with the control group with score of 205.9 versus 121.1 (<jats:italic>t<\/jats:italic>\u2010value 2.12, <jats:italic>p<\/jats:italic>\u2010value 0.021). There was no difference in the PD\u2010L1 score between the JAK2 negative versus the control group 187.2 versus 121.1 (<jats:italic>t<\/jats:italic>\u2010value 1.02, <jats:italic>p<\/jats:italic>\u2010value 0.162).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings suggest that PMF patients with a JAK2 mutation have a higher PD\u2010L1 expression in megakaryocytes compared with the control group. We postulate that the combination of checkpoint and JAK2 inhibitors may be an active treatment option in JAK2 mutated PMF given the higher PD\u2010L1 expression.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.2054","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T07:50:06Z","timestamp":1725522606000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Programmed death\u2010ligand 1 expression in patients with primary or secondary myelofibrosis"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-2380","authenticated-orcid":false,"given":"Moayed","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Murphree","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirtesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Delta Pathology Group  Shreveport Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Mastrodomenico","sequence":"additional","affiliation":[{"name":"Delta Pathology Group  Shreveport Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Safah","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine Tulane University  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Schmid","sequence":"additional","affiliation":[{"name":"Pathology Department Tulane University  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4002-9284","authenticated-orcid":false,"given":"Francisco","family":"Socola","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplant University of California Davis  Sacramento California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"e_1_2_11_2_1","first-page":"44","volume-title":"WHO Classification of tumours of Haematopoietic and Lymphoid Tissues","author":"Thiele J","year":"2008"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.04.012"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2016.17.3.923"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.005"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7729"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.240"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005491"},{"issue":"12","key":"e_1_2_11_12_1","article-title":"Phase II study of single agente nivoulmab in patients with myelofibrosis","volume":"100","author":"Dall IA","year":"2021","journal-title":"Ann Hematol"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.2054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T08:22:03Z","timestamp":1727425323000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.2054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/cnr2.2054"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.2054","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2023-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2054"}}